Search

Displaying results 3671 - 3680 of 5759 in total
  1. Drug

    Evixapodlin

    go.drugbank.com/drugs/DB21520
    Investigational

    Evixapodlin has a monoisotopic molecular weight of 690.22 Da.

  2. Drug

    Regadenoson

    go.drugbank.com/drugs/DB06213
    ApprovedInvestigational

    Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

    Categories: Purinergic P1 Receptor Agonists
  3. Drug

    Velufenacin

    go.drugbank.com/drugs/DB21473
    Investigational

    Velufenacin has a monoisotopic molecular weight of 362.12 Da. … Velufenacin is under investigation in clinical trial NCT05282069 (A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder).

  4. Drug

    SO-101

    go.drugbank.com/drugs/DB05345
    Experimental

    Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.

  5. Drug

    Vabametkib

    go.drugbank.com/drugs/DB21629
    Investigational

    Vabametkib has a monoisotopic molecular weight of 566.3 Da.

  6. Drug

    Vemtoberant

    go.drugbank.com/drugs/DB21607
    Investigational

    Vemtoberant has a monoisotopic molecular weight of 619.2 Da.

  7. Drug

    Delocamten

    go.drugbank.com/drugs/DB21711
    Investigational

    Delocamten has a monoisotopic molecular weight of 377.16 Da.

  8. Drug

    Alofanib

    go.drugbank.com/drugs/DB20918
    Investigational

    Alofanib has a monoisotopic molecular weight of 413.07 Da.

  9. Drug

    Asapiprant

    go.drugbank.com/drugs/DB20492
    Investigational

    Asapiprant has a monoisotopic molecular weight of 501.16 Da.

  10. Drug

    WP-1122

    go.drugbank.com/drugs/DB17192
    Investigational

    WP-1122 is a prodrug of 2-deoxy-D-glucose (2-DG). It was granted FDA orphan designation for the treatment of glioblastoma multiforme.[L47361]